Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Outcomes of a trifocal intraocular lens implantation: results of a prospective clinical trial

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Multifocal I

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 08:18

Venue: Auditorium A

First Author: : I.Bahar ISRAEL

Co Author(s): :                        

Abstract Details

Purpose:

To report the visual outcomes in patients with cataract surgery and bilateral implantation of a trifocal intraocular lens (IOL) in a prospective clinical trial.

Setting:

Ophthalmology Department, Rabin Medical Center, Petach Tiqva, Israel

Methods:

Patients with cataract and less than 0.75 diopter (D) of corneal astigmatism were enrolled to the study and received bilateral implantation of Finevision Pod F trifocal IOLs. Outcome measures included monocular and binocular uncorrected and best corrected distance (UDVA), intermediate (UIVA), and near (UNVA) visual acuities in photopic and mesopic conditions ; refractive outcomes; binocular defocus curve; and spectacle independence.

Results:

Three months postoperatively, the mean binocular photopic UDVA, UIVA, and UNVA in 20 eyes of 10 patients were 0. 1 logMAR ± 0.11 (SD), 0.05 ± 0.05 logMAR, and 0.02 ± 0.03 logMAR, respectively. Preoperative spherical equivalent (SE) was +0.21±2.02 D (range : -3.88 to +1.75D) and postoperative spherical equivalent was -0.18±0.31 (range: -0.75 to 0.13 D) The trifocal defocus curve showed vision of 0.2 logMAR or better in the range of +1.5D to -2.5 D of defocus. Complete spectacle independence was reported by 90% of patients.

Conclusions:

This study showed excellent visual outcomes with the trifocal IOL, with very good outcomes at the intermediate and near distance.

Financial Disclosure:

... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous